Ensuring quality and resilient supply

Providing reliable access to medicines, nutrition and technologies through global capabilities and robust supply networks.

We take our role in producing essential medicines very seriously. We work closely with industry partners and actively collaborate with supply chain stakeholders in forums such as the End Drug Shortages Alliance and in partnership with associations like the Association for Accessible Medicines (AAM) to bring awareness to the issues that cause drug shortages and to find solutions. Building a more resilient supply for critical drugs starts with predictability. Working together, stakeholders across the supply chain can dramatically improve stewardship of these critical drugs by establishing a resiliency standard that emphasizes price and reliability in equal measure. 

Our local-for-local production approach in key regions such as Europe and the United States contributes to supply security and responsiveness. Twice in the past two decades, serious recalls and supply disruptions threatened the availability of heparin in the United States, putting patient care at risk. On both occasions, Pharma played a leading role by rapidly scaling supply, implementing careful allocation and proactive planning, and working closely with stakeholders to help maintain continuity of care and avert broader shortages.

Our capabilities have been recognized through awards for our track record of supply stability in key markets. In 2025, Fresenius Kabi US received two awards from Vizient, including the Supply Assurance award – an important recognition of the company’s commitment to long-term, sustainable drug and technologies supply.

Learn more about Pharma

Clearly, patients can only benefit from our biosimilar therapies if they’re available and affordable as needed. Building from our broader Fresenius Kabi manufacturing and commercial infrastructure in over 100 countries1, our vertically integrated value chain makes this possible. This enables us to drive the development process, from R&D through to manufacturing, supply chain and commercialization, and remain committed to uncompromising product and service quality, efficacy, speed and safety.

Our investment in mAbxience has been core to strengthening our pipeline and enhancing our biologic production capabilities and capacity. We’re now able to master manufacturing process technology transfers and move from development to drug manufacturing faster, at lower cost and with more flexibility than ever.

We have invested heavily over five years to expand our internal drug substance and drug product manufacturing capacity and embedded automation and lean-manufacturing good practices. These have enabled us to achieve a sustainable 33% reduction in end-to-end lead times, an average increase by +10% in conversion yields, and deliver as much as 50% savings in some areas.2 Our internal manufacturing capacity including mAbxience, is completed by a strong external network built mainly around a few strategic supply partners. Along the improvement program, we have also identified and implemented further performance improvement plans with our contract manufacturing organizations.

We have an ambitious program in place over the next 12 months to transform our supply chain to improve its speed, reliability, and agility to better respond to biosimilar market dynamics and our customers' expectations across the world. An agile, responsive supply chain is critical in tender-led European markets, in particular. It’s also accelerating our growth in the U.S., and enabling us to scale launches globally as we aim to double our portfolio by 2030.2

 

 

References:

1. Fresnius Annual Report (2025). Available at: fresenius.com/sites/default/files/2026-03/fresenius_annual_report_2025.pdf [last accessed June 2026] 

2. Assessing the Biosimilar Void (2023). Available at: Assessing the Biosimilar Void | IQVIA [last accessed June 2026] 

Learn more about our Biopharma

Our position as a provider of parenteral, oral, and enteral nutrition, enables coordinated supply and integrated solutions for healthcare providers. These capabilities are supported by over 60 years' experience in medical nutrition and established manufacturing systems designed to meet high regulatory and quality standards.

Continuity of supply is essential to ensure that patients receive consistent nutritional support. We combine global capabilities with local manufacturing in the US and Europe to support reliable delivery and consistent product quality, with regional innovation hubs in Germany, China, and India.

Learn more about Nutrition

Our solutions are at the heart of critical therapies and care pathways. When therapies are time-sensitive, healthcare providers trust us to support chronically ill patients at their most vulnerable, while providing options to help reduce errors, shorten recovery times and improve overall care. Active worldwide, our production capabilities, technical excellence and world class support enable us to deliver the quality, availability and performance that help healthcare systems flow smoothly, consistently and efficiently. 

Our global footprint includes multiple plants, dual-sourcing and local-to-local manufacturing, helping us deliver quality-assured reliability and supply resilience. Technical services and support infrastructure keep systems functioning at peak performance, which in turn helps reduce downtime and protect clinical flow. Our proven abilities can be seen in our many long-term, contract-based relationships with customers, including major plasma collectors and leading hospitals, who rely on us to ensure uninterrupted operations even in challenging times. 

Learn more about MedTech